Early BCG-Denmark and Neonatal Mortality Among Infants Weighing < 2500 g: A Randomized Controlled Trial
Top Cited Papers
Open Access
- 30 September 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 65 (7), 1183-1190
- https://doi.org/10.1093/cid/cix525
Abstract
Background. BCG vaccine may reduce overall mortality by increasing resistance to nontuberculosis infections. In 2 randomized trials in Guinea-Bissau of early BCG-Denmark (Statens Serum Institut) given to low-weight (LW) neonates (<2500 g at inclusion) to reduce infant mortality rates, we observed a very beneficial effect in the neonatal period. We therefore conducted the present trial to test whether early BCG-Denmark reduces neonatal mortality by 45%. We also conducted a meta-analysis of the 3 BCG-Denmark trials. Methods. In 2008-2013, we randomized LW neonates to "early BCG-Denmark" (intervention group; n = 2083) or "control" (local policy for LW and no BCG-Denmark; n = 2089) at discharge from the maternity ward or at first contact with the health center. The infants were randomized (1: 1) without blinding in blocks of 24. Data was analyzed in Cox hazards models providing mortality rate ratios (MRRs). We had prespecified an analysis censoring follow-up at oral poliovirus vaccine campaigns. Results. Early administration of BCG-Denmark was associated with a nonsignificant reduction in neonatal mortality rate (MRR, 0.70; 95% confidence interval [ CI],.47-1.04) and a 34% reduction (0.66;.44-1.00) when censoring for oral poliovirus vaccine campaigns. There was no reduction in mortality rate for noninfectious diseases, but a 43% reduction in infectious disease mortality rate (MRR, 0.57; 95% CI,.35-.93). A meta-analysis of 3 BCG trials showed that early BCG-Denmark reduced mortality by 38% (MRR, 0.62; 95% CI,.46-.83) within the neonatal period and 16% (0.84;.71-1.00) by age 12 months. Conclusion. Early administration of BCG-Denmark in LW infants is associated with major reductions in mortality rate. It is important that all LW infants receive early BCG in areas with high neonatal mortality rates.This publication has 35 references indexed in Scilit:
- Effect of the Newhints home-visits intervention on neonatal mortality rate and care practices in Ghana: a cluster randomised controlled trialThe Lancet, 2013
- Nonspecific Effects of Vaccines and the Reduction of Mortality in ChildrenClinical Therapeutics, 2013
- Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytesProceedings of the National Academy of Sciences of the United States of America, 2012
- The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in UgandaVaccine, 2012
- Small Randomized Trial Among Low–birth-weight Children Receiving Bacillus Calmette-Guérin Vaccination at First Health Center ContactThe Pediatric Infectious Disease Journal, 2012
- Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey dataThe Lancet, 2009
- Effect of 50 000 IU vitamin A given with BCG vaccine on mortality in infants in Guinea-Bissau: randomised placebo controlled trialBMJ, 2008
- Genome plasticity of BCG and impact on vaccine efficacyProceedings of the National Academy of Sciences of the United States of America, 2007
- BCG vaccination scar associated with better childhood survival in Guinea-BissauInternational Journal of Epidemiology, 2005
- New Ballard Score, expanded to include extremely premature infantsThe Journal of Pediatrics, 1991